an 3199

AN3199 is a selective inhibitor of PDE4 with an IC50 of 94.5 nM.

DBCO-HS-PEG2-VA-PABC-SG3199 is a drug-linker conjugate for ADC (antibody-drug conjugate) that features a SG3199-based DNA minor groove cross-linking agent and a cleavable linker. This compound is suitable for the synthesis of ADCs.

AZD-3199, a β2 adrenergic receptor agonist, is used potentially for the treatment of asthma and chronic obstructive.

SG3199 is a PBD dimer which binds in the minor groove of DNA, and forms covalent DNA interstrand cross-links in naked linear plasmid DNA. SG3199 is potently cytotoxic against a panel of human solid tumour and haematological cancer cell lines.

AZD-3199 dihydrobromide is a β2 adrenergic receptor agonist potentially for the treatment of asthma and chronic obstructive.

SG3199-Val-Ala-PAB is an intermediate in the synthesis of Tesirine, a conjugate of agent-linker for antibody-drug conjugates (ADCs) used in cancer research [1].

Compound B7-H4-ADC (Mal-amido-PEG8-Val-Ala-PAB-SG3199) is a Drug-Linker Conjugate for ADC that not only inhibits cancer cell proliferation but also induces apoptosis, arrests the cell cycle, and damages DNA [1].

BCN-HS-PEG2-VA-PABC-SG3199 (Compound 4) functions as a pyrrolobenzodiazepine-based agent linker for antibody-drug conjugates (ADC) [1]. This compound also serves as a click chemistry reagent, featuring a BCN group capable of participating in strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules.